225 related articles for article (PubMed ID: 15709899)
1. Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy.
Borges N
Expert Opin Drug Saf; 2005 Jan; 4(1):69-73. PubMed ID: 15709899
[TBL] [Abstract][Full Text] [Related]
2. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004554. PubMed ID: 15495119
[TBL] [Abstract][Full Text] [Related]
3. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.
Borges N
Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845
[TBL] [Abstract][Full Text] [Related]
4. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
Deane KH; Spieker S; Clarke CE
Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
Benabou R; Waters C
Expert Opin Drug Saf; 2003 May; 2(3):263-7. PubMed ID: 12904105
[TBL] [Abstract][Full Text] [Related]
6. Tolcapone: new drug. In Parkinson's disease: unacceptable risk of severe hepatitis.
Prescrire Int; 2006 Apr; 15(82):54-7. PubMed ID: 16604736
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
Kaakkola S
Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
[TBL] [Abstract][Full Text] [Related]
8. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
[TBL] [Abstract][Full Text] [Related]
9. Influence of COMT inhibition on levodopa pharmacology and therapy.
Goetz CG
Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
[TBL] [Abstract][Full Text] [Related]
10. COMT inhibition in the treatment of Parkinson's disease.
Ruottinen HM; Rinne UK
J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
[TBL] [Abstract][Full Text] [Related]
11. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Kaakkola S
Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
[TBL] [Abstract][Full Text] [Related]
12. Tolcapone in the management of Parkinson's disease.
Leegwater-Kim J; Waters C
Expert Opin Pharmacother; 2006 Nov; 7(16):2263-70. PubMed ID: 17059382
[TBL] [Abstract][Full Text] [Related]
13. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
15. COMT inhibition: a new treatment strategy for Parkinson's disease.
Kurth MC; Adler CH
Neurology; 1998 May; 50(5 Suppl 5):S3-14. PubMed ID: 9591516
[TBL] [Abstract][Full Text] [Related]
16. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
[TBL] [Abstract][Full Text] [Related]
17. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
[TBL] [Abstract][Full Text] [Related]
18. Role of tolcapone in the treatment of Parkinson's disease.
Leegwater-Kim J; Waters C
Expert Rev Neurother; 2007 Dec; 7(12):1649-57. PubMed ID: 18052761
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
Jorga KM
Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
[TBL] [Abstract][Full Text] [Related]
20. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
Sabaté M; Bosch A; Pedrós C; Figueras A
Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
[No Abstract] [Full Text] [Related]
[Next] [New Search]
